-

09:26:18 AM

ALGS Stock News

ALGS - Aligos Therapeutics Inc

10/14/21 4:58 PM

Nasdaq : ALGS

conferences

Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting® 2021

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced upcoming poster presentations

RHEA-AI

neutral

10/11/21 8:00 AM

Nasdaq : ALGS

clinical trial

Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel

RHEA-AI

neutral

09/20/21 4:05 PM

Nasdaq : ALGS

conferences

Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D.,

RHEA-AI

neutral

08/05/21 4:05 PM

Nasdaq : ALGS

earnings

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results

Raised $83.6 million in gross proceeds from common stock offering STOPS™ and CAM programs: initial data presented at conferences, dosing in 2 nd CHB cohorts ongoing Clinical trial application filed for 3 rd CHB drug candidate ALG-0202572 (antisense oligonucleotide) – dosing in HVs anticipated in Q4

RHEA-AI

neutral

07/29/21 4:05 PM

Nasdaq : ALGS

Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the

RHEA-AI

neutral

06/30/21 10:08 PM

Nasdaq : ALGS

offering

Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has granted the

RHEA-AI

neutral

06/28/21 4:10 PM

Nasdaq : ALGS

offering

Aligos Therapeutics Announces Proposed Public Offering of Common Stock

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option to purchase up

RHEA-AI

neutral

06/21/21 8:00 AM

Nasdaq : ALGS

conferencesclinical trial

Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress 2021

Aligos Therapeutics, Inc. (Nasdaq:

RHEA-AI

neutral

06/14/21 8:00 AM

Nasdaq : ALGS

conferences

Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021

-Five scientific posters to be presented at upcoming EASL ILC meeting - All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to enter clinical development in

RHEA-AI

neutral

06/10/21 7:00 AM

Nasdaq : ALGS

conferences

Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference

RHEA-AI

neutral

ALGS Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.aligos.com
Security nameAligos Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees80
Tags
- Health Technology
- Pharmaceuticals: Major

ALGS Description:

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.